Drug Trial Radar · NCT06633835
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
660
Actual
Start
Sep 19, 2024
Primary completion
Dec 30, 2024
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- NovavaxIndustry
- Sponsor type
- Industry
- Collaborators
- University of Utah
- First posted
- Oct 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
Conditions
- COVID-19
- Vaccine-Preventable Diseases
- SARS CoV 2 Infection
Interventions
protein subunit: Novavax COVID-19 vaccineBiological
Participants will receive a single dose (0.5 ml) of study vaccine Novavax COVID-19 vaccine, 2024-2025 formula (JN.1 containing) in the deltoid muscle of the arm.
Pfizer mRNA COVID-19 vaccineBiological
Participants will receive a single dose (0.3 ml) of study vaccine Pfizer mRNA COVID-19 vaccine, 2024-2025 formula (KP.2 containing) in the deltoid muscle of the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with solicited systemic reactogenicity symptoms.Time frame: Day 0 to Day 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Utah School of Medicine
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.